ReCode Therapeutics is back with an additional $50 million more than a year after it raised a $120 million Series B.
The Menlo Park, CA-based biotech is developing new mRNA treatments, and the key, it believes, is the delivery system. ReCode’s platform engineers lipid nanoparticles — the fatty acid…
Click here to view original post
